HighVista Strategies’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-40,020
| Closed | -$2.89M | – | 174 |
|
|
2025
Q4 | $2.89M | Sell |
40,020
-25,560
| -39% | -$1.65M | 0.74% | 44 |
|
|
2025
Q3 | $2.86M | Buy |
65,580
+24,716
| +60% | +$999K | 0.7% | 41 |
|
|
2025
Q2 | $1.16M | Sell |
40,864
-13,326
| -25% | -$397K | 0.43% | 100 |
|
|
2025
Q1 | $1.6M | Hold |
54,190
| – | – | 0.62% | 61 |
|
|
2024
Q4 | $1.58M | Buy |
54,190
+41,686
| +333% | +$1.74M | 0.59% | 60 |
|
|
2024
Q3 | $574K | Buy |
+12,504
| New | +$543K | 0.2% | 115 |
|
|
2023
Q2 | – | Sell |
-16,733
| Closed | -$257K | – | 150 |
|
|
2023
Q1 | $257K | Buy |
+16,733
| New | +$368K | 0.21% | 97 |
|
|
2022
Q4 | – | Sell |
-17,334
| Closed | -$283K | – | 123 |
|
|
2022
Q3 | $283K | Sell |
17,334
-7,530
| -30% | -$144K | 0.16% | 96 |
|
|
2022
Q2 | $361K | Sell |
24,864
-28,300
| -53% | -$421K | 0.22% | 85 |
|
|
2022
Q1 | $982K | Buy |
53,164
+8,870
| +20% | +$151K | 0.62% | 34 |
|
|
2021
Q4 | $1.05M | Sell |
44,294
-12,558
| -22% | -$300K | 0.84% | 43 |
|
|
2021
Q3 | $1.4M | Buy |
+56,852
| New | +$1.24M | 0.93% | 22 |
|
|
2021
Q2 | – | Sell |
-31,797
| Closed | -$693K | – | 135 |
|
|
2021
Q1 | $693K | Buy |
31,797
+5,132
| +19% | +$126K | 0.52% | 40 |
|
|
2020
Q4 | $680K | Buy |
26,665
+9,463
| +55% | +$276K | 0.43% | 56 |
|
|
2020
Q3 | $484K | Buy |
+17,202
| New | +$497K | 0.35% | 51 |
|
Other funds holding RNAM
HighVista Strategies's RNAM Position: Q1 2026 in Review
HighVista Strategies sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 40,020 shares — an estimated $2.89M sold.
HighVista Strategies first reported a position in RNAM in Q3 2020 and held it in 15 quarters. The position peaked at $2.89M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- HighVista Strategies reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- HighVista Strategies sold 40,020 Avidity Biosciences shares in Q1 2026, an estimated $2.89M.
- HighVista Strategies first reported a position in Avidity Biosciences in Q3 2020 and held it in 15 quarters.
- HighVista Strategies's Avidity Biosciences position peaked at $2.89M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.